Regeneron Pharmaceuticals, Inc.
REGNNASDAQHealthcare● Active
$635.45
+$6.72(+1.07%)
Market Cap$65.5B
P/E Ratio—
52W High$821.11
52W Low$476.49
Regeneron Pharmaceuticals, Inc. (REGN) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · REGN · as of 2026-06-08
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| Depreciation & Amort. | $0.54B | $0.48B | $0.42B | $0.34B | $0.29B |
| Stock-Based Comp. | $0.99B | $0.98B | $0.89B | $0.72B | $0.60B |
| Change in Working Capital | $0.53B | ($0.62B) | ($0.09B) | ($0.24B) | ($1.92B) |
| Net Cash from Operations | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B |
| Investing Activities | |||||
| Capital Expenditure | ($0.90B) | ($0.76B) | ($0.93B) | ($0.59B) | ($0.55B) |
| Purchases of Investments | ($10.96B) | ($16.62B) | ($11.65B) | ($7.49B) | ($7.05B) |
| Sales of Investments | $11.55B | $15.03B | $9.44B | $5.55B | $2.22B |
| Net Cash from Investing | ($0.63B) | ($2.47B) | ($3.19B) | ($3.78B) | ($5.38B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($3.97B) | ($3.63B) | ($2.94B) | ($2.53B) | ($2.68B) |
| Dividends Paid | ($0.37B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | ($3.72B) | ($2.20B) | ($1.79B) | ($1.01B) | ($1.01B) |
| Free Cash Flow | |||||
| Free Cash Flow | $4.08B | $3.66B | $3.67B | $4.42B | $6.53B |
| FCF Margin %(computed) | 28.45% | 25.80% | 27.96% | 36.35% | 40.63% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Regeneron Pharmaceuticals, Inc. data
About Regeneron Pharmaceuticals, Inc. (REGN) Cash Flow Statement
Regeneron Pharmaceuticals, Inc. generated operating cash flow of $4.98B and free cash flow of $4.08B for 2025 — a FCF margin of 28.45%. Capital expenditure was ($0.90B).
Frequently asked questions
REGN · 4 questionsRegeneron Pharmaceuticals, Inc. generated free cash flow of $4.08B for 2025, up 11.3% year-over-year.
REGN free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08